Biotechnology
Artiva Biotherapeutics is a clinical-stage, publicly-traded biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company's lead program, AlloNK®, is an allogeneic, off-the-shelf NK cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity and drive B-cell depletion, delivered in the outpatient setting without requiring hospitalization. AlloNK is currently being evaluated in three ongoing clinical trials for B-cell driven autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and other conditions. Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. The company was founded in 2019 as a spin-out of GC Cell with exclusive worldwide rights to their NK cell manufacturing technology.
Industry
Biotechnology
Company Size
51-200 employees
Founded
2019
Beta · Sourced from candidate reports
Be the first to share your experience with Artiva Biotherapeutics.
Your reply helps other candidates know what to expect.
